This bill adds a new Chapter 4 to Title 1 of the U.S. Code that bars the expenditure of any federal funds—including funds in federal trust funds—on ‘‘gender transition procedures’’ as the bill defines them. The prohibition reaches direct federal provision of care in federal facilities and by federal employees, and it also bars federal funds from paying for health benefits plans that include such coverage.
The bill also amends the Internal Revenue Code and Affordable Care Act authorities to deny premium tax credits, cost‑sharing reductions, and the small‑employer health insurance expense credit for qualified health plans that include coverage for those procedures. It permits the purchase of separate coverage paid entirely with non‑federal funds, but prohibits use of Medicaid matching funds or ACA credits to pay for that coverage.
The measure’s dense definitions and broad procedural list make operational and compliance choices complex for insurers, states, employers, and federal benefit programs.
At a Glance
What It Does
The bill prohibits expenditure of federal funds (including trust funds) on a long enumerated list of hormonal and surgical interventions the text calls ‘‘gender transition procedures,’’ and bars federal facilities and employees from furnishing them. It also amends tax and ACA provisions to make plans that cover those procedures ineligible for premium tax credits, cost‑sharing reductions, and the small‑employer credit.
Who It Affects
Federal benefit programs, Medicaid and other federally subsidized plans, Exchanges and multi‑state plans, private insurers that participate in ACA programs, employers who sponsor health plans, and individuals seeking covered transition‑related care.
Why It Matters
It replaces program‑level discretion with a statutory spending ban and cross‑cuts ACA financial incentives, forcing payers to restructure plan designs or segregate coverage. The bill’s definitional choices will determine practical scope and create compliance burdens across federal, state, and private coverage systems.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new standalone chapter into Title 1 of the U.S. Code that establishes a categorical rule: no federal money may be spent on the procedures the statute labels ‘‘gender transition procedures.’’ That prohibition is framed broadly to capture appropriated funds and monies in trust funds, which means agencies must review whether benefit payments and program expenditures fall within the ban. The statute also forbids federal health facilities and employees from providing those procedures.
The heart of the bill is its definitions. ‘‘Gender transition procedure’’ is defined to include a long list of hormonal therapies (for example, puberty blockers and cross‑sex hormones at what the bill calls ‘‘supraphysiologic’’ doses) and dozens of named surgical interventions, from orchiectomy and vaginoplasty to mastectomy, voice surgery, liposuction, and a catch‑all for ‘‘the removal of any otherwise healthy or non‑diseased body part or tissue.’’ The definition also contains multiple exclusions: treatments for disorders of sex development (DSDs), treatment of complications that arise from prior procedures, medically necessary emergency procedures certified by a physician, prescriptions for precocious puberty, and routine male circumcision.Title II translates the ground rule into the ACA and tax code. It amends IRC section 36B and the structure governing cost‑sharing reductions so that premium tax credits and related advance payments cannot be used to buy qualified health plans that include the banned coverage; it similarly narrows the small‑employer health insurance expense credit.
The bill adds language that requires multi‑state plans in Exchanges not to provide such coverage. At the same time, it permits non‑federal actors—individuals, employers, insurers, states, or localities—to offer or buy separate coverage for the listed procedures, but only if those premiums and payments come entirely from non‑federal sources and they are not financed with Medicaid matching funds or ACA tax credits.Practically, the measure forces a funding‑source test: a plan or benefit that would trigger federal spending or federal premium assistance cannot include the enumerated procedures.
Insurers and program administrators will need to decide whether to remove items from benefit packages, carve them into a separately priced, non‑federally subsidized rider, or exit certain markets. States that currently use state funds to supplement federal programs will face restrictions on using federal matching dollars to cover separable benefits for these procedures.
The bill sets a delayed application for the tax‑code amendments (effective for plan years beginning after one year from enactment), but the statutory chapter otherwise stands as the operative prohibition for covered federal funds.
The Five Things You Need to Know
The bill adds a new Chapter 4 to Title 1 that bars any funds authorized or appropriated by Federal law—and funds in any trust fund receiving such federal funds—from being expended for the statute’s defined ‘‘gender transition procedures.’, The statutory definition lists both hormonal interventions (e.g.
GnRH agonists and cross‑sex hormones at supraphysiologic doses) and an extensive menu of named surgeries (including orchiectomy, vaginoplasty, mastectomy, phalloplasty, metoidioplasty, and many facial and cosmetic procedures), plus a catch‑all for removal of otherwise healthy tissue.
Exemptions narrow the ban in three principal ways: (1) care for individuals with medically verifiable disorders of sex development (DSDs); (2) treatment of complications caused or exacerbated by prior transition procedures; and (3) certain emergency or medically necessary interventions and prescriptions for precocious puberty; male circumcision is explicitly excluded.
The bill amends IRC section 36B and the small‑employer credit rules (section 45R) to disallow premium tax credits, advance payments, cost‑sharing reductions, and the small‑employer health insurance expense credit for qualified plans that include the prohibited coverage, and it instructs the multi‑state plan program to avoid offering such coverage.
The statute allows individuals, employers, insurers, or states to purchase separate coverage for the listed procedures only when paid entirely with non‑federal funds, and it expressly forbids using Medicaid matching funds or ACA credits to finance that separate coverage.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Creates a standalone statutory chapter that codifies the funding ban
This provision inserts an entire new chapter into Title 1 with numbered sections (§301–§307). Structurally that means the funding ban is located in the U.S. Code (not left as a rider or appropriations limitation), which affects statutory interpretation, notice to agencies, and how agencies search the Code for applicable constraints. Agencies administering health programs will treat the chapter as a primary source for whether an expenditure is permitted.
Broad prohibition on federal funds and trust funds
Section 301 uses broad language: ‘‘No funds authorized or appropriated by Federal law, and none of the funds in any trust fund to which funds are authorized or appropriated by Federal law, shall be expended’’ for listed procedures. The inclusion of trust funds means programs financed in whole or part through dedicated receipts (for example, certain Medicare or other trust‑fund arrangements) require a funding‑source assessment before covering listed services.
Bans health benefits coverage and federal provider delivery
Section 302 bars federal funds from being expended for health benefits coverage that includes the procedures, which reaches federal contract or grant payments that subsidize private coverage. Section 303 prevents federal facilities and federal employees acting within the scope of employment from furnishing the procedures, which directly affects veteran, military, and other federal health systems unless they rely exclusively on non‑federal funds for a separate product.
Permits separate non‑federally financed coverage—but not with federal matching funds
These companion sections allow private purchasers, states, localities, or insurers to create separate coverage or plans covering the procedures so long as payment comes entirely from non‑federal sources. Critically, the statute bars use of matching funds required for federally subsidized programs (explicitly citing Medicaid matching) to finance such separate coverage, closing a potential backdoor funding route.
Treatment of complications carved out
Section 306 clarifies that the prohibition does not apply to treatment of infections, injuries, diseases, or disorders caused by or exacerbated by prior gender transition procedures. That carve‑out addresses acute and follow‑up clinical care, but it will require recordkeeping and billing distinctions between initial transition care and complication treatment.
Definitions: sex, male, female, gender transition, and enumerated procedures
Section 307 contains key interpretive definitions. It defines ‘‘sex’’ biologically (male/female tied to reproductive system functions), sets a working definition of ‘‘gender transition,’’ and furnishes a detailed—extensive—list of procedures counted as ‘‘gender transition procedures,’’ while also listing specific exclusions (DSD care, complication treatment, precocious‑puberty drugs, male circumcision). Those definitions will anchor compliance and litigation about scope.
ACA and tax‑code implementation: disallow credits and adjust multi‑state plan rules
This title amends IRC section 36B to exclude qualified health plans that include the listed procedures from eligibility for premium tax credits and advance payments, inserts an analogous bar for cost‑sharing reduction compatibility, amends the small‑employer credit (45R) to exclude plans with such coverage, and adds a requirement that multi‑state plans not provide benefits for which federal funding is prohibited. The tax changes take effect for plan years beginning after one year from enactment.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- States or localities that wish to restrict taxpayer exposure — They gain a statutory restriction on use of federal funds and a clear federal rule that prevents federal matching dollars from being used to subsidize such coverage.
- Insurers and third‑party administrators that offer segregated, unsubsidized riders — The bill creates a market for separate, non‑federally financed products; carriers can price and sell riders outside the ACA subsidy system.
- Federal budget and program managers seeking explicit statutory constraints — Agencies receive a clear Code citation to justify discontinuing payments or coverage and to reallocate budgets away from covered services.
Who Bears the Cost
- Individuals seeking transition‑related care, particularly Medicaid and Exchange enrollees — They lose access to federal funding and subsidies for the enumerated procedures unless their state or employer wholly pays outside federal programs.
- State Medicaid programs and providers — States that currently pay for such services with a combination of state and federal funds will face practical limits because Medicaid matching funds may not be used to finance separate coverage for these services.
- Insurers offering ACA‑qualified plans and employers sponsoring health plans — Plans that include the listed procedures will be ineligible for premium tax credits and the small‑employer credit, creating financial and competitive pressure to redesign benefits or create segregated non‑federal riders.
- Federal health systems and their clinicians — Veterans Health Administration, DoD medical facilities, and federal employee health plans must stop furnishing the listed procedures within the scope of federal employment, potentially shifting care to non‑federal providers and affecting provider revenues and referrals.
Key Issues
The Core Tension
The central dilemma is a statutory choice between strict fiscal control and program uniformity on one hand, and preserving access to medically indicated care and respecting clinical judgment on the other; the bill solves for the former by imposing a bright‑line funding ban, but that choice forces administrative splitting of benefits, creates medically fraught coverage classifications, and shifts costs or care pathways to non‑federal payers with no simple way to reconcile competing priorities.
The bill’s operational complexity rests largely in its definitional mechanics and its funding‑source test. ‘‘No funds authorized or appropriated by Federal law’’ and the inclusion of trust funds sweep broadly, but they leave open interpretive questions about mixed‑fund situations. For example, if a state pays a portion of a patient’s care and Medicaid contributes the remainder, the statute’s bar on using Medicaid matching funds to finance separate coverage creates administrability challenges: states and providers will need systems to segregate claims and revenue sources to show no federal money touched a covered procedure.
That segregation is administratively costly and potentially error prone.
The long procedural list includes routine interventions that insurers and clinicians often classify as general surgical or cosmetic services (e.g., liposuction, augmentation mammoplasty, lipofilling, or even vasectomy and tubal ligation). How payers treat these procedures when performed for reasons other than ‘‘gender transition’’ will require careful medical‑coding rules and attestations.
The statute’s medical exemptions (DSDs, complication treatment, precocious puberty, emergency care) narrow the ban, but implementing those exemptions will require new clinical criteria, prior‑authorization pathways, and documentation standards to prevent improper denial of care or improper subsidy claims.
Finally, the text creates a tension between federal spending controls and the real‑world need to address complications or medically necessary treatments related to prior care. Although complication treatment is permitted under §306, determining whether a condition is causally linked to a prior transition procedure will often be clinically contested.
That ambiguity opens the door to disputes between payers and providers and could produce coverage delays for acute care that Congress ostensibly intended to protect.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.